Developer docs
API playgroundTry for free, no card

Search company profiles

TomoWave Laboratories

Full company profile

uuid0004r8n

Namestring
TomoWave Laboratories
Legal namestring
TomoWave Laboratories, Inc.
Websiteurl
tomowave.com
Company typeenum
Private
Founded yearint
1993
Descriptiontext

TomoWave Laboratories, Inc. is a privately held medical imaging company headquartered at 7505 Fannin Street, Suite 500, Houston, Texas. Founded in 2010 around technology invented by Dr. Alexander Oraevsky in 1993, the company develops proprietary optoacoustic (photoacoustic) tomography and laser ultrasound systems. Its core technology integrates optical excitation with ultrasonic detection to deliver high-resolution 3D volumetric imaging with both anatomical and functional/molecular information (blood content, oxygen saturation, molecular composition), without ionizing radiation or toxic contrast agents. The product portfolio includes the LOIS-3D preclinical mouse imaging system for biomedical research, the LOUISA-3D clinical breast imaging system (in development with MD Anderson Cancer Center conducting clinical trials), and additional platforms (Maestro, Symphony).

TomoWave's customers are primarily preclinical research institutions and clinical healthcare providers, with named validation partners including MD Anderson Cancer Center and Moores Cancer Center at UC San Diego. The company reports a $19M preclinical sales lead funnel and 16 validated customers in total, with technology protected across 8 international patent families. Revenue mechanics are hardware sales of specialized preclinical imaging systems sold through direct enterprise field sales on a quote basis; clinical products remain pre-commercial and are not yet FDA-cleared.

The company is currently raising a Series A convertible note to execute on its preclinical sales pipeline and advance commercial development and regulatory approvals for its clinical products, including the LOUISA-3D breast imaging system and pipeline 4D laser optoacoustic ultrasonic systems targeting diagnostics, image-guided surgery, and thermal therapy monitoring. Management is led by Dr. Alexander Oraevsky (Founder, CEO/CTO), supplemented by Angelo Ferrario (COO/CFO) and MedTech veterans from Medtronic, J&J, and Danaher. As of 2025, TomoWave was recognized by Healthcare Tech Outlook Magazine as the Top Company in Optoacoustic Imaging.

Short descriptiontext

TomoWave Laboratories develops proprietary optoacoustic tomography and laser ultrasound imaging systems for preclinical research and clinical applications, primarily serving cancer research institutions and hospitals targeting cancer detection and vascular disease imaging.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
optoacoustic imaging systems, photoacoustic tomography, preclinical imaging equipment, clinical breast imaging, laser ultrasound systems
Industry1 code
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging Equipment
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Preclinical Imaging Systems
TypeHardware Sales
Description

Sale of LOIS-3D preclinical research imaging systems for small animal imaging with reported sales lead funnel valued at $19M

tomowave.com
2Clinical Imaging Systems (Pipeline)
TypeHardware Sales
Description

Development of clinical products including LOUISA-3D breast imaging system and 4D laser optoacoustic ultrasonic systems for diagnostics, image-guided surgery, and therapy monitoring

tomowave.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1LOIS-3D
Description

Laser Optoacoustic Imaging System for pre-clinical mouse imaging

tomowave.com
+3 more records
Core offering1 text field

TomoWave develops and manufactures proprietary optoacoustic tomography and laser ultrasound imaging systems that combine functional/molecular and anatomical imaging. The product portfolio spans the LOIS-3D preclinical mouse imaging system, the LOUISA-3D clinical breast imaging system, and additional Maestro and Symphony imaging platforms, enabling non-invasive cancer detection and image-guided interventions without ionizing radiation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Spatial resolution of 150 microns equal in all 3 dimensions
+3 more records
Product overview1 text field

TomoWave Laboratories develops proprietary optoacoustic tomography and laser ultrasound imaging systems for combined functional/molecular and anatomical imaging. The product portfolio consists of pre-clinical and clinical imaging systems: LOIS-3D (pre-clinical mouse imaging for research), LOUISA-3D (clinical breast cancer imaging), Maestro and Symphony (additional imaging systems). The technology integrates optical excitation with ultrasound detection to provide high-resolution tissue images without ionizing radiation or toxic contrast agents.

Product and service1 record
1LOIS-3D Pre-Clinical Imaging System
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key validation partner for LOUISA-3D Clinical Breast Imaging project currently conducting clinical trials. MD Anderson is one of the world's most respected cancer research institutions, providing credibility for clinical validation.

2Moores Cancer Center at UC San Diego
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cancer center validating TomoWave's optoacoustic imaging technology for clinical applications.

tomowave.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NIH-funded collaboration for LOIS-3D technology development with Professor Mark Anastasio in the Department of Biomedical Engineering.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Professor Kirill Larin at the Cullen College of Engineering Department of Biomedical Engineering.

5Universidad Carlos III de Madrid (Professor Horacio Lamela Rivera)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

International academic collaboration for optoacoustic imaging research.

tomowave.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with UTMB Department of Ophthalmology and Visual Sciences Center for Biomedical Engineering.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

NanoLISA project collaboration for optoacoustic sensor development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

iThera Medical is a direct competitor in optoacoustic/photoacoustic imaging, offering preclinical MSOT in-vivo imaging systems and exploring clinical translation for oncology and inflammatory diseases. Both companies commercialize laser-based optoacoustic tomography using ultrasound detection, competing for the same research and translational imaging budgets.

TypeDirect peer
Description

Seno Medical is a direct competitor in optoacoustic breast cancer imaging, commercializing the Imagio breast imaging system that combines optoacoustic imaging with ultrasound. It targets the identical clinical workflow and dense-breast diagnostic niche as TomoWave's LOUISA-3D.

TypeEmerging player
Description

Endra is an emerging player developing thermoacoustic imaging for fatty liver disease and preclinical imaging applications. Like TomoWave, Endra is commercializing photoacoustic-derived modalities and pursuing clinical partnerships, but with a narrower clinical focus.

TypeBroad incumbent
Description

Fujifilm VisualSonics is a broad incumbent in high-frequency preclinical ultrasound and photoacoustic imaging (Vevo systems), serving cardiovascular and cancer research. It is a comparative vendor for academic buyers choosing between traditional ultrasound and optoacoustic modalities for preclinical research.

TypeBroad incumbent
Description

Hologic is a broad incumbent in mammography and breast imaging with the dominant installed base in 3D tomosynthesis systems. Any new breast imaging entrant must compete against Hologic's sales channel, reimbursement infrastructure, and customer relationships for the same hospital radiology budgets.

TypeBroad incumbent
Description

GE HealthCare is a broad incumbent across ultrasound, mammography, and molecular imaging with global distribution and clinical evidence networks. Its installed ultrasound base represents both a partnership channel and a competitive threat for optoacoustic breast imaging.

TypeBroad incumbent
Description

Siemens Healthineers is a broad incumbent in medical imaging including ultrasound, mammography, and emerging photon-counting CT. It competes for capital imaging budgets and could acquire or build optoacoustic capability to extend its breast imaging portfolio.

TypeBroad incumbent
Description

Philips is a broad incumbent in ultrasound (including dedicated breast imaging systems) and a participant in image-guided interventions. Its enterprise sales channel is a benchmark for TomoWave's commercial ambitions in clinical imaging.

TypeEmerging player
Description

PhotoSound Technologies is an emerging player providing preclinical photoacoustic imaging instruments and OEM components. It overlaps with TomoWave in optoacoustic subsystem supply and small-animal imaging but does not currently offer clinical breast systems.

TypeBroad incumbent
Description

Bruker is a broad incumbent in preclinical imaging systems including MRI and PET/CT. Academic and pharma research buyers evaluating TomoWave's LOIS-3D frequently benchmark against Bruker's installed base of small-animal imaging modalities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TomoWave Laboratories

Medical Imaging Equipmenttomowave.com

TomoWave Laboratories develops proprietary optoacoustic tomography and laser ultrasound imaging systems for preclinical research and clinical applications, primarily serving cancer research institutions and hospitals targeting cancer detection and vascular disease imaging.

What TomoWave Laboratories does

TomoWave Laboratories, Inc. is a privately held medical imaging company headquartered at 7505 Fannin Street, Suite 500, Houston, Texas. Founded in 2010 around technology invented by Dr. Alexander Oraevsky in 1993, the company develops proprietary optoacoustic (photoacoustic) tomography and laser ultrasound systems. Its core technology integrates optical excitation with ultrasonic detection to deliver high-resolution 3D volumetric imaging with both anatomical and functional/molecular information (blood content, oxygen saturation, molecular composition), without ionizing radiation or toxic contrast agents. The product portfolio includes the LOIS-3D preclinical mouse imaging system for biomedical research, the LOUISA-3D clinical breast imaging system (in development with MD Anderson Cancer Center conducting clinical trials), and additional platforms (Maestro, Symphony).

TomoWave's customers are primarily preclinical research institutions and clinical healthcare providers, with named validation partners including MD Anderson Cancer Center and Moores Cancer Center at UC San Diego. The company reports a $19M preclinical sales lead funnel and 16 validated customers in total, with technology protected across 8 international patent families. Revenue mechanics are hardware sales of specialized preclinical imaging systems sold through direct enterprise field sales on a quote basis; clinical products remain pre-commercial and are not yet FDA-cleared.

The company is currently raising a Series A convertible note to execute on its preclinical sales pipeline and advance commercial development and regulatory approvals for its clinical products, including the LOUISA-3D breast imaging system and pipeline 4D laser optoacoustic ultrasonic systems targeting diagnostics, image-guided surgery, and thermal therapy monitoring. Management is led by Dr. Alexander Oraevsky (Founder, CEO/CTO), supplemented by Angelo Ferrario (COO/CFO) and MedTech veterans from Medtronic, J&J, and Danaher. As of 2025, TomoWave was recognized by Healthcare Tech Outlook Magazine as the Top Company in Optoacoustic Imaging.

TomoWave Laboratories firmographics

Firmographics
Name
TomoWave Laboratories
Legal name
TomoWave Laboratories, Inc.
Website
https://tomowave.com
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
1–10 employees
Short description
TomoWave Laboratories develops proprietary optoacoustic tomography and laser ultrasound imaging systems for preclinical research and clinical applications, primarily serving cancer research institutions and hospitals targeting cancer detection and vascular disease imaging.
Ownership category
akta.pro rank

TomoWave Laboratories industry classification

Industry
Product category
Medical Imaging Equipment
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Optoacoustic imaging systems
  • Photoacoustic tomography
  • Preclinical imaging equipment
  • Clinical breast imaging
  • Laser ultrasound systems

Where TomoWave Laboratories is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TomoWave Laboratories business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Preclinical Imaging Systems: Sale of LOIS-3D preclinical research imaging systems for small animal imaging with reported sales lead funnel valued at $19M
  2. Clinical Imaging Systems (Pipeline): Development of clinical products including LOUISA-3D breast imaging system and 4D laser optoacoustic ultrasonic systems for diagnostics, image-guided surgery, and therapy monitoring

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

TomoWave Laboratories product offering

Product offering

Core offering

TomoWave develops and manufactures proprietary optoacoustic tomography and laser ultrasound imaging systems that combine functional/molecular and anatomical imaging. The product portfolio spans the LOIS-3D preclinical mouse imaging system, the LOUISA-3D clinical breast imaging system, and additional Maestro and Symphony imaging platforms, enabling non-invasive cancer detection and image-guided interventions without ionizing radiation.

Product overview

TomoWave Laboratories develops proprietary optoacoustic tomography and laser ultrasound imaging systems for combined functional/molecular and anatomical imaging. The product portfolio consists of pre-clinical and clinical imaging systems: LOIS-3D (pre-clinical mouse imaging for research), LOUISA-3D (clinical breast cancer imaging), Maestro and Symphony (additional imaging systems). The technology integrates optical excitation with ultrasound detection to provide high-resolution tissue images without ionizing radiation or toxic contrast agents.

Differentiator

Problem solved

Functional benefit

Brands

  • LOIS-3D: Laser Optoacoustic Imaging System for pre-clinical mouse imaging
  • LOUISA-3D
  • Maestro
  • Symphony

Products and services

  • LOIS-3D Pre-Clinical Imaging System

Quantifiable outcome

  • Spatial resolution of 150 microns equal in all 3 dimensions
  • +3 more outcomes

Companies that use TomoWave Laboratories

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

TomoWave Laboratories technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

TomoWave Laboratories partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • MD Anderson Cancer CentercoreStrategic or Co-development PartnerKey validation partner for LOUISA-3D Clinical Breast Imaging project currently conducting clinical trials. MD Anderson is one of the world's most respected cancer research institutions, providing credibility for clinical validation.
  • Moores Cancer Center at UC San DiegocoreStrategic or Co-development PartnerCancer center validating TomoWave's optoacoustic imaging technology for clinical applications.
  • University of Illinois Urbana Champaign (Professor Mark Anastasio)coreStrategic or Co-development PartnerNIH-funded collaboration for LOIS-3D technology development with Professor Mark Anastasio in the Department of Biomedical Engineering.
  • University of Houston (Professor Kirill Larin)minorStrategic or Co-development PartnerCollaboration with Professor Kirill Larin at the Cullen College of Engineering Department of Biomedical Engineering.
  • Universidad Carlos III de Madrid (Professor Horacio Lamela Rivera)minorStrategic or Co-development PartnerInternational academic collaboration for optoacoustic imaging research.
  • UTMB (Professor Massoud Motamedi)minorStrategic or Co-development PartnerCollaboration with UTMB Department of Ophthalmology and Visual Sciences Center for Biomedical Engineering.
  • University of Texas Health Science Center at San Antonio (Professor Randy Glickman)minorStrategic or Co-development PartnerNanoLISA project collaboration for optoacoustic sensor development.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

TomoWave Laboratories competitors and assessment

Company assessment

Direct peers

  • iThera Medical: iThera Medical is a direct competitor in optoacoustic/photoacoustic imaging, offering preclinical MSOT in-vivo imaging systems and exploring clinical translation for oncology and inflammatory diseases. Both companies commercialize laser-based optoacoustic tomography using ultrasound detection, competing for the same research and translational imaging budgets.
  • Seno Medical Instruments: Seno Medical is a direct competitor in optoacoustic breast cancer imaging, commercializing the Imagio breast imaging system that combines optoacoustic imaging with ultrasound. It targets the identical clinical workflow and dense-breast diagnostic niche as TomoWave's LOUISA-3D.

Emerging players

  • Endra Life Sciences: Endra is an emerging player developing thermoacoustic imaging for fatty liver disease and preclinical imaging applications. Like TomoWave, Endra is commercializing photoacoustic-derived modalities and pursuing clinical partnerships, but with a narrower clinical focus.
  • PhotoSound Technologies: PhotoSound Technologies is an emerging player providing preclinical photoacoustic imaging instruments and OEM components. It overlaps with TomoWave in optoacoustic subsystem supply and small-animal imaging but does not currently offer clinical breast systems.

Broad incumbents

  • Fujifilm VisualSonics: Fujifilm VisualSonics is a broad incumbent in high-frequency preclinical ultrasound and photoacoustic imaging (Vevo systems), serving cardiovascular and cancer research. It is a comparative vendor for academic buyers choosing between traditional ultrasound and optoacoustic modalities for preclinical research.
  • Hologic: Hologic is a broad incumbent in mammography and breast imaging with the dominant installed base in 3D tomosynthesis systems. Any new breast imaging entrant must compete against Hologic's sales channel, reimbursement infrastructure, and customer relationships for the same hospital radiology budgets.
  • GE HealthCare: GE HealthCare is a broad incumbent across ultrasound, mammography, and molecular imaging with global distribution and clinical evidence networks. Its installed ultrasound base represents both a partnership channel and a competitive threat for optoacoustic breast imaging.
  • Siemens Healthineers: Siemens Healthineers is a broad incumbent in medical imaging including ultrasound, mammography, and emerging photon-counting CT. It competes for capital imaging budgets and could acquire or build optoacoustic capability to extend its breast imaging portfolio.
  • Philips Healthcare: Philips is a broad incumbent in ultrasound (including dedicated breast imaging systems) and a participant in image-guided interventions. Its enterprise sales channel is a benchmark for TomoWave's commercial ambitions in clinical imaging.
  • Bruker BioSpin / Preclinical Imaging: Bruker is a broad incumbent in preclinical imaging systems including MRI and PET/CT. Academic and pharma research buyers evaluating TomoWave's LOIS-3D frequently benchmark against Bruker's installed base of small-animal imaging modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

TomoWave Laboratories social profiles

Digital presence

TomoWave Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TomoWave Laboratories leadership team

Management profile

Number of profiles

Profiles2 records

TomoWave Laboratories funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TomoWave Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TomoWave Laboratories

What does TomoWave Laboratories do?

TomoWave develops and manufactures proprietary optoacoustic tomography and laser ultrasound imaging systems that combine functional/molecular and anatomical imaging. The product portfolio spans the LOIS-3D preclinical mouse imaging system, the LOUISA-3D clinical breast imaging system, and additional Maestro and Symphony imaging platforms, enabling non-invasive cancer detection and image-guided interventions without ionizing radiation.

Is TomoWave Laboratories a public or private company?

TomoWave Laboratories is a private company. It is classified as venture growth investor backed and is currently operating.

When was TomoWave Laboratories founded?

TomoWave Laboratories was founded in 1993. It employs 1 to 10 people.

Where is TomoWave Laboratories based?

TomoWave Laboratories is headquartered in Houston, United States, in the North America region.

How does TomoWave Laboratories make money?

Two revenue lines are on record. Preclinical Imaging Systems are the primary driver. The others are clinical Imaging Systems (Pipeline).

Who are TomoWave Laboratories's main competitors?

Direct peers on record are iThera Medical and Seno Medical Instruments. Emerging players are Endra Life Sciences and PhotoSound Technologies. Broad incumbents are Fujifilm VisualSonics, Hologic, GE HealthCare, Siemens Healthineers, Philips Healthcare and Bruker BioSpin / Preclinical Imaging.

Does TomoWave Laboratories have an API?

No public API is recorded for TomoWave Laboratories.

What industry is TomoWave Laboratories in?

TomoWave Laboratories's product category is Medical Imaging Equipment. Its primary akta.pro industry code is HLAHABAF, Mammography & Breast Imaging Systems. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals